Abstract
Prostate cancer (PrCa) is one of the most genetically driven solid cancers with heritability estimates as high as 57%. African American men are at an increased risk of PrCa; however, current risk prediction models are based on European ancestry groups and may not be broadly applicable. In this study, we define an African ancestry group of 4,533 individuals to develop an African ancestry-specific PrCa polygenic risk score (PRState). We identified risk loci on chromosomes 3, 8, and 11 in the African ancestry group GWAS and constructed a polygenic risk score (PRS) from 10 African ancestry-specific PrCa risk SNPs, achieving an AUC of 0.61 [0.60-0.63] and 0.65 [0.64-0.67], when combined with age and family history. Performance dropped significantly when using ancestry-mismatched PRS models but remained comparable when using trans-ancestry models. Importantly, we validated the PRState score in the Million Veteran Program, demonstrating improved prediction of PrCa and metastatic PrCa in African American individuals. This study underscores the need for inclusion of individuals of African ancestry in gene variant discovery to optimize PRS.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
his research was supported by the Million Veteran Program MVP022 award #I01 CX001727 (PI: Richard L. Hauger MD). This publication does not represent the views of the Department of Veterans Affairs or the United States Government. This work was supported by National Institutes of Health grants #1F30CA247168, #T32CA067754 to Meghana S. Pagadala and an Emerging Leader Award from The Mark Foundation for Cancer Research grant #18-022-ELA to Hannah Carter.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data analyzed in this study were obtained from dbgap (accession id: phs001120.v1.p1) and Million Veteran Program, Office of Research and Development, Veterans Health Administration. Access to raw genotype and phenotype data can be obtained through application.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
DISCLOSURES: The authors declare no potential conflicts of interest
Data Availability
Summary statistics are within the manuscript and Supporting Information files. The data analyzed in this study were obtained from dbgap (accession id: phs001120.v1.p1) and Million Veteran Program, Office of Research and Development, Veterans Health Administration. Access to raw genotype and phenotype data can be obtained through application.
